@article {Goga2021.12.21.21268171, author = {Ameena Goga and Linda-Gail Bekker and Nigel Garrett and Tarylee Reddy and Nonhlanhla Yende-Zuma and Lara Fairall and Harry Moultrie and Azwidihwi Takalani and Valentina Trivella and Mark Faesen and Veronique Bailey and Ishen Seocharan and Glenda E Gray and on behalf of the Sisonke Study Team}, title = {Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa}, elocation-id = {2021.12.21.21268171}, year = {2021}, doi = {10.1101/2021.12.21.21268171}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background We report breakthrough infections (BTIs) during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers (HCW) participating in the Sisonke phase 3B Ad26.COV2.S vaccine trial (ClinicalTrials.gov number, NCT04838795). Data were gathered between 17 February and 15 December 2021. Duration of each period in this study was 89 days for Beta, 180 days or Delta and 30 days for Omicron.Results A total of 40 538 BTIs were observed, with 609 during Beta, 22 279 during Delta and 17 650 during Omicron. By 15 December, daily infections during Omicron were three times that seen during the peak observed during Delta. However, unlike the Delta period, with Omicron there was a clear and early de-coupling of hospitalisation from cases as a percentage of the Delta peak curves. Omicron significantly infected a greater proportion of HCW in the 18-30 year age-group, compared with the 55+ age group. There were 1 914 BTI-related hospitalisations - 77, 1 429 and 408 in the Beta (89 days), Delta (180 days) and Omicron (30 days) periods, respectively. During Omicron, 91\% hospitalized HCWs required general ward care, 6\% high care and 3\% intensive care, compared with 89\% general ward care, 4\% high care and 7\% intensive care, during Delta and 78\% general care, 7\% high care and 16\% intensive care during Beta (p\<0.001). During Beta and Beta 43\% of hospitalized HCW needed supplementary oxygen and 7-8\% needed ventilation, compared with 16\% and 0.2\% respectively during the Omicron period (p\<0.001). Median length of hospitalization was significantly lower with Omicron compared with Beta and Delta (3 days compared with 5-6 days, p\<0.001).Conclusions We illustrate more BTIs but reassuringly less severe Covid-19 with Omicron. Re-infections and Omicron-driven primary infections were likely driven by high population SARS-CoV-2 seroprevalence, waning vaccine effectiveness over time, increased Omicron infectivity, Omicron immune evasion or a combination of these and need further investigation. Follow-up of this cohort will continue and reports will be updated, as time and infections accrue.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04838795Funding StatementThe study was funded by the National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael \& Susan Dell Foundation, The Elma Vaccines and Immunization Foundation, Grant number 21-V0001, and the Bill \& Melinda Gates Foundation, Grant number INV-030342. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South African Medical Research Council Human Research Ethics Committee gave ethical approval for the studyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2021/12/22/2021.12.21.21268171}, eprint = {https://www.medrxiv.org/content/early/2021/12/22/2021.12.21.21268171.full.pdf}, journal = {medRxiv} }